Tottenham Acquisition I today filed supplemental details in its proxy to shareholders in advance of a Dec. 30 vote on whether to merge with Clene Nanomedicine. The additional information outlines the exercise of options and share conversions that will impact the number of issuable shares post-merger. Read more.
Tottenham Amends Proxy on Clene Merger to Disclose Share Conversions
